Roche abandons potential blockbuster cholesterol drug

After a review of lackluster efficacy data, Roche has thrown in the towel on developing one of the most promising drug candidates in the company's vast pipeline, dalcetrapib. And the Swiss drug giant'…
Read the full story: News